COR Cencora
Oligopoly toll collector on US drug spend; fairly priced if specialty mix lifts margins to about 1.3%.
The story
Cencora is one of three US drug wholesalers that together control over 90% of the market. The oligopoly has scale and regulatory moats, and it earns thin but very stable margins on huge volumes. Specialty distribution (oncology and physician practices), GLP-1 pass-through volume, and services businesses like animal health and biopharma consulting drive growth. It is a mature, cash-generative compounder with high returns on capital, not a high-growth story.
Specialty drugs and GLP-1s keep top-line growth high, near the 10% five-year CAGR, before it fades to inflation-like 3%. Margin rises modestly from about 0.8% reported (1.2% TTM) to 1.3% as specialty mix and services offset low-margin GLP-1 volume, which is still below peak-adjusted levels. Sales-to-capital is set at 20 rather than the observed 36 to allow for working-capital needs and tuck-in M&A. The baseline DCF's 0.8% margin cannot reconcile with a $65B market cap; at about 1.3% and roughly 9% growth, the gap closes to a plausible range.
Value drivers
| Revenue growth (Y1) | 9.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 1.3% |
| Years to target margin | 4 |
| Sales-to-capital | 6.00 |
| Beta | 0.80 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.3% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | -1.54B |
| PV of terminal value | 34.48B |
| Equity value | 28.82B |
| ÷ shares → per share | $151.01 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 362.72B | 9.0% | 1.3% | 3.16B | 4.99B | -1.84B | -1.70B |
| 2 | 392.26B | 8.1% | 1.3% | 3.46B | 4.92B | -1.47B | -1.25B |
| 3 | 420.84B | 7.3% | 1.3% | 3.75B | 4.76B | -1.01B | -796.64M |
| 4 | 447.89B | 6.4% | 1.3% | 4.04B | 4.51B | -466.73M | -339.83M |
| 5 | 472.84B | 5.6% | 1.3% | 4.27B | 4.16B | 108.46M | 72.95M |
| 6 | 495.13B | 4.7% | 1.3% | 4.47B | 3.72B | 753.41M | 468.08M |
| 7 | 514.23B | 3.9% | 1.3% | 4.64B | 3.18B | 1.46B | 836.72M |
| 8 | 529.66B | 3.0% | 1.3% | 4.78B | 2.57B | 2.21B | 1.17B |
Key risks
- GLP-1 and branded pass-through volume inflates revenue but dilutes margin, and manufacturer fee renegotiation could squeeze spreads
- Drug pricing policy (IRA negotiation, PBM reform, tariffs) compresses wholesale economics or reroutes distribution
- Customer concentration with Walgreens, plus residual opioid litigation and settlement cash outflows
Catalysts
- Continued specialty and oncology share gains plus the MSO/physician services rollups (RCA, OneOncology) lifting mix
- Biosimilar adoption, which carries higher distributor margins than branded drugs